Catalyst Event
AbbVie Inc (ABBV) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
3/17/2026, 12:00:00 AM
The FDA rejected Aldeyra Therapeutics' dry eye disease drug, reproxalap, for which AbbVie holds an exclusive commercialization option, citing a lack of substantial evidence of efficacy.
Korean Translation
AbbVie가 독점 상업화 옵션을 보유한 Aldeyra Therapeutics의 안구건조증 치료제 레프록살랍이 효능에 대한 실질적인 증거 부족을 이유로 FDA의 승인을 받지 못함.
Related Recent Events
CrowdStrike Holdings Inc (CRWD) · Earnings Release
Next earnings release for Q1 2027 is scheduled for 2026-06-09, with analysts forecasting an EPS of $1.07 estimated.
6/9/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart's earnings release for Q1 FY2027 is scheduled. A medium impact is estimated as earnings releases are key volatility drivers for retail stocks, expected.
5/21/2026, 12:00:00 AM
ONEOK Inc (OKE) · Other
ONEOK 2026 Annual Meeting of Shareholders on May 20, 2026, scheduled.
5/20/2026, 12:00:00 AM
Fair Isaac Corporation (FICO) · Other
FICO World 2026 is scheduled to take place from May 19-22, 2026.
5/19/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Google I/O 2026 developer conference is scheduled for 2026-05-19. Developer conferences usually have a 1-5% price impact. Updates on AI, Gemini, and Android are expected.
5/19/2026, 12:00:00 AM